MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Biogen Inc

Abierto

SectorSalud

118.4 -0.91

Resumen

Variación precio

24h

Actual

Mínimo

117.21

Máximo

119.98

Métricas clave

By Trading Economics

Ingresos

-122M

267M

Ventas

-15M

2.5B

P/B

Media del Sector

10.42

57.333

BPA

3.44

Margen de beneficio

10.865

Empleados

7,605

EBITDA

-158M

536M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+51.84% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-4.2B

17B

Apertura anterior

119.31

Cierre anterior

118.4

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Biogen Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 sept 2024, 11:00 UTC

Principales Noticias

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29 may 2024, 15:56 UTC

Ganancias
Adquisiciones, fusiones, absorciones

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Comparación entre iguales

Cambio de precio

Biogen Inc Esperado

Precio Objetivo

By TipRanks

51.84% repunte

Estimación a 12 meses

Media 181.46 USD  51.84%

Máximo 265 USD

Mínimo 121 USD

De acuerdo con 29 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Biogen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

29 ratings

14

Comprar

15

Mantener

0

Vender

Puntuación técnica

By Trading Central

118.83 / 119.99Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.